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ABSTRACT
Background. Selection of patients with anal cancer for
groin irradiation is based on tumor size, palpation, ultra-
sound, and ﬁne needle cytology. Current staging of anal
cancer may result in undertreatment in small tumors and
overtreatment of large tumors. This study reports the fea-
sibility of the sentinel lymph node biopsy (SLNB) in
patients with anal cancer and whether this improves the
selection for inguinal radiotherapy.
Methods. A total of 50 patients with squamous anal can-
cer were evaluated prospectively. Patients without a SLNB
(n = 29) received irradiation of the inguinal lymph nodes
based on lymph node status, tumor size, and location of the
primary tumor. Inguinal irradiation treatment in patients
with a SLNB was based on the presence of metastases in
the SLN.
Results. SLNs were found in all 21 patients who under-
went a SLNB. There were 5 patients (24%) who had
complications after SLNB and 7 patients (33%) who had a
positive SLN and received inguinal irradiation. However, 2
patients with a tumor-free SLN and no inguinal irradiation
developed lymph node metastases after 12 and 24 months,
respectively.
Conclusions. We conclude that SLNB in anal cancer is
technically feasible. SLNB can identify those patients who
would beneﬁt from refrain of inguinal irradiation treatment
and thereby reducing the incidence of unnecessary inguinal
radiotherapy. However, because of the occurrence of
inguinal lymph node metastases after a tumor-negative
SLNB, introduction of this procedure as standard of care in
all patients with anal carcinoma should be done with cau-
tion to avoid undertreatment of patient who otherwise
would beneﬁt from inguinal radiotherapy.
The incidence of anal carcinoma is 4–7 per 1 million
with a peak incidence between 58 and 64 years of age.
Anal carcinoma is associated with chronic anorectal dis-
orders, immunosuppression, and with the presence of
Human Papilloma Virus. Of all patients presenting with
anal carcinoma, 36% have T3–T4 tumors.
1 Synchronous
inguinofemoral metastasis are observed in 11% of all
patients presenting with an anal carcinoma and in 10% of
those treated with curative intent.
1 The presence of lymph
node metastasis in anal cancer is associated with a poor
prognosis. Because surgery is reserved for persistent and
recurrent disease, and removal of the inguinofemoral
lymph nodes is not initially performed, there is little data
on the histologic nodal status of patients that present
with anal carcinoma. The current standard treatment for
synchronous inguinal lymph node metastases is chemoir-
radiation of the inguinofemoral lymph node basins, and the
occurrence of locoregional metastases can be controlled in
90% of patients.
2 This leads to an important ﬁnding that
early detection of inguinal lymph node metastases is
therefore clinically relevant in anal carcinoma.
Assessing the lymph node involvement by clinical
examination alone in the inguinofemoral region solely by
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metastases measure\5 mm in diameter.
3 Ultrasound (US)
is signiﬁcantly more reliable compared with palpation with
a reported sensitivity of 36% to 87% and a speciﬁcity
ranging from 56% to 89%.
4 The addition of ﬁne-needle
aspiration (FNA) cytology may increase the detection rate
of lymph node metastases up to 65%.
5 However, consid-
ering the small size of the inguinal metastasis, even when
all modalities are combined (i.e., clinical examination,
ultrasound, computerized tomography [CT] scanning, MRI,
FNA cytology), not all cases of nodal involvement will be
detected. Clearly, there is a need for early and accurate
detection of lymph node involvement that could select
those patients who could beneﬁt the most from inguinal
radiotherapy for locoregional control. This could reduce
the morbidity of unnecessary inguinal radiotherapy in these
patients without lymph node involvement. A possible
technique to solve this problem is the sentinel lymph node
biopsy (SLNB). Sentinel lymph node biopsy has been used
the improve the detection rate of lymph node metastases in
patient with cutaneous squamous cell carcinoma in the
anogenital region as recently reviewed by Ross et al.
6 The
detection rate of the sentinel lymph node (SLN) was 97%
with 24% of the SLNBs being positive for tumor cells. The
false-negative rate, as determined by subsequent lym-
phadenectomy irrespective of SLN status, appeared to be
4%.
6 However, in patients with anal cancer there is very
limited evidence of the applicability of SLNB. Most studies
lack sufﬁcient follow-up and do not include their clinical
decision making on the basis of the SLNB status. As a
consequence, this would imply irradiation of the groin in
every positive SLNB, irrespective of tumor size and, con-
sequently, for patients with a negative SLNB no irradiation
on the groin.
This study describes the technical feasibility of the
SLNB technique in patients with squamous anal carcinoma
and the effect of inguinal irradiation treatment based on the
SLNB status with sufﬁcient follow-up.
PATIENTS AND METHODS
Patient Group
Between 2001 and 2008, 50 patients (27 women and 23
men, mean age 60 years, range 34–88 years) with histop-
athologically proven squamous carcinoma of the anal canal
and anal margin were prospectively enrolled in the study
after informed consent. The inguinal region was staged
with palpation and US followed by US-guided cytology in
case of suspected lymph nodes. Patients with positive
inguinal lymph nodes on cytology were not eligible for the
sentinel lymph node protocol. Patients were staged for
distant metastases with ultrasonography of the liver and
chest X-ray or a CT scan of the abdomen and thorax.
Patients with evidence of distant metastasis were also
excluded from the study. Tumor size was determined by
endoscopy, endosonography, or MRI according to the
World Health Organization (WHO) recommendations for
anal cancer.
7 Patients with T4 tumors or without written
informed consent were excluded from the sentinel lymph
node protocol. Of the 50 patients, 21 were eligible for a
SLNB. The remaining 29 patients were included in the
follow-up for evaluation of clinical outcome after standard
treatment. Figure 1 summarizes the patient selection for
SLNB.
Lymphatic Mapping and Sentinel Lymph Node Biopsy
Onedaypriortosurgery,0.5 mL100 mBq
99mTc-labeled
nanocolloid (Nanocoll: Amersham Cygne, Eindhoven, The
Netherlands) was injected intradermal in 3–4 locations
around the primary tumor. For tumors in the anal canal, the
99mTc-nanocolloid was injected in 4 locations around the
anus. For imaging purposes, a single-headed gamma camera
(Diacam, Siemens, Hoffmann Estates, IL) was used equip-
ped with low-energy all-purpose collimator. The energy
window was centered on the
99mTc-photopeak of 140 keV,
using a 15% window. Zoom factor was 1, image matrix
128 9 128 pixels for dynamic, and 256 9 256 pixels for
static acquisition. Anterior images of the pelvic and ingu-
inofemoral region were obtained. Within 5 min after
injection, dynamic imaging was started with 30-s frames
during 30 min.An anterior and lateral static image (bilateral
in case of double-sided lymph nodes) was obtained 2.5–3 h
postinjection. In order to facilitate interpretation, transmis-
sion scanning was performed simultaneously using the
120 keV gamma rays of a
57Co ﬂood source. The ﬁrst-
appearing persistent focal accumulation was considered to
beaSLN.ThesiteoftheSLNwasmarkedwithawaterproof
pencil on the overlying skin. On the day of surgery and fol-
lowing induction of anesthesia, approximately 0.5–2.0 ml
Patent Blue (Laboratoire Guerbet, Aulney-Sous-Bois,
France)wasinjectedsubcutaneouslyinthesamelocationsas
thenanocolloid, *5–10 minpriortothe surgical procedure.
The SLNB was guided by a handheld gamma ray detection
probe (Neoprobe, Johnson & Johnson Medical, Hamburg,
Germany) and by dissection of blue-stained lymph vessels.
When identiﬁcation of the SLN was not successful because
of low radioactivity during the operative procedure, the use
of Patent Blue was relied on. The blue nodes found in this
manner were checked for radioactivity after excision. After
removal of the SLN(s), the biopsy bed was re-examined for
radioactivity. Lymph nodes that appeared to be affected by
palpation, eveniftheywere notradioactiveorblue, andblue
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evaluated for the presence of tumor cells.
Histopathological Examination
Lymph nodes \0.5 cm in diameter were included in
whole, those C0.5 and \1 cm were cut in half and
imbedded completely, and lymph nodes C1 cm were
lamellated and processed to parafﬁn blocks for hematox-
ylin and eosin (H&E) staining. SLNs that were negative on
H&E staining were stained by immunohistochemistry
(cytokeratin antibody AE1/3) at 250 lm intervals sections
at 3 levels.
Treatment
Patients received irradiation of the primary tumor and
locoregional lymph nodes (single dose 1.8 Gy, 25 frac-
tions, boost primary tumor and involved lymph nodes;
single dose 1.8 Gy, 8 fractions) combined with chemo-
therapy using 5-ﬂuorouracil/mitomycine-C or capecitabine/
mitomycine-C. Patients with small tumors T1 (B2 cm) and
no nodal involvement did not receive irradiation of the
inguinal lymph nodes. Node-negative T2 tumors with
growth conﬁned to the anal canal were inspected by the
radiotherapist and were considered for radiotherapy of the
primary tumor alone.
Irradiation treatment of the patients in the SLNB group
was based on the inguinal lymph node status irrespective of
their T-stage. If the SLNB was positive, the radiation ﬁeld
was extended to the inguinal lymph nodes. In cases of
negative SLNB, the patient received standard treatment of
the primary tumor if large enough without irradiation of the
inguinal lymph nodes.
Radiation without chemotherapy (n = 14) was given in
selected patients with stage T1 or contraindications for
chemotherapy. Follow-up for all patients was every
3 months with a median follow-up period of 31 months
(range 20–90 months). Follow-up consisted of visual
inspection and palpation of the primary tumor side and the
groin region.
RESULTS
Patient Characteristics and TNM Stage
Of the 50 patients enrolled, 21 underwent the SLNB
procedure. Of the patients in the SLNB group, the majority
had stage T2 primary tumors (2 were T1, 15 were T2, 4
were T3) (Fig. 1). In the patients with a SLNB, US of the
50 patients with anal cancer
16  no informed consent 
for SLNB
21 informed consent
for SLNB
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FIG. 1 Selection of patients for
SLNB and inguinal
radiotherapy and the incidence
of inguinal lymph node
recurrence after completion of
treatment
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US-guided ﬁne-needle cytology of these lymph nodes was
overall negative. However, 2 of these 4 patients with
negative ﬁne needle cytology had a positive SLNB and
received irradiation of the inguinal region.
The 29 patients without a SLNB had mainly T2 and T3
tumors (2 were T1, 12 were T2, 10 were T3, 5 were T4). Of
these patients, 11 had lymph node involvement detected by
palpation or US followed by US-guided cytology (Fig. 1).
Sentinel Lymph Node Detection
All 21 patients showed 1 or more SLNs on the preop-
erative lymphoscintigram. Of the 21, 7 patients (33%) had
a unilateral SLN and 14 (67%) showed bilateral SLNs on
the lymphoscintigram. A total of 58 SLNs were seen on the
lymphoscintigram. Of the 58 SLNs, 43 (75%) of the lymph
nodes seen on the lymphoscintigram were detected with
Patent Blue staining; 53 of the 58 lymph nodes identiﬁed
on the lymphoscintigram (91%) were detected with the
handheld gamma probe.
Of 21 patients, 7 (33%) had tumor metastases in the
SLNB. Also, 5 of 21 patients (23%) had complications after
the SLNB; 2 patients experienced wound infection, 2 had
seroma, and 1 patient developed lymphedema of the leg. Of
these 5 patients, 4 had a positive SLN and had to undergo
irradiation of the groin. Radiotherapy of the groin had to be
postponed for several weeks in all cases of wound infection.
Treatment and Tumor Response
The standard treatment of patients with anal cancer
consisted of a combination of irradiation and chemotherapy
in 37 patients (74%) (21 without a SLNB and 16 with a
SLNB procedure). Of the patients who received chemo-
therapy, 51% received a combination of 5-ﬂuorouracil and
mitomycine-C and 49% a combination of capecitabine and
mitomycine-C. Chemotherapy treatment was stopped for 3
patients after 1 dose because of side effects. All patients
received irradiation therapy of the primary tumor. A total
of 45 of the patients (90%) had a complete response (CR;
deﬁned as no residual tumor found by visual inspection and
palpation) after treatment of the primary tumor. Of the 5
patients (10%) (all without a SLNB) with a partial response
(PR) 4 developed distant metastases within 1 year of initial
treatment and therefore refrained from salvage surgery.
The other patient with a partial response was treated with
an abdominal perineal resection.
Of the patients without a SLNB, all 13 patients with
lymph node metastasis or a T4 tumor received irradiation
of the inguinal lymph nodes. Of clinical node-negative
patients without informed consent for a SLNB, 75% (12 of
16) received irradiation of the inguinal lymph nodes based
on the tumor size and tumor localization. In the group of
patients with a SLNB, 33% (7 of 21) of patients were
treated with extension of the irradiation ﬁeld to the ingu-
inofemoral region based on a tumor positive SLNB
(Fig. 1). Complications after irradiation of the inguinofe-
moral region consisted mainly of moderated or severe
epidermolysis of the skin. Of the 32 patients who received
irradiation of the inguinofemoral region, 15 (47%) had
grade 1 and 17 (53%) developed grade 2 complications.
Outcomes and Survival
Of the patients with a SLNB, 2 of 14 (14%) developed
inguinal lymph node metastases despite a negative SLNB
basedonhistopathology.Theﬁrstpatientwasan81-year-old
man with a left lateral T1 tumor of 1 cm and 1 SLN on
the lymphoscintigram. The SLNB showed a blue and
radioactive SLN on the right side without tumor cells at
histopathological examination. As a consequence, the
patient received irradiation of the primary tumor without
additional chemotherapy and showed a complete response.
The second patient was a 67-year-old man with a left lateral
T2 tumor of 4 cm. Clinical examination did not reveal sus-
pected lymph nodes. On CT of the abdomen there were
suspecteddeepiliaclymphnodes,butCT-guidedﬁne-needle
aspiration was negative for tumor cells. The lymphoscinti-
gram showed 3 SLNs on the right side and one SLN on the
left side. The SLNB itself showed 3 blue ? radioactive
SLNs on the right side that were tumor negative at histopa-
thology.NoblueorradioactiveSLNcouldbedetectedonthe
left side. The patient received irradiation of the primary
tumor with capecitabine/Mitomycine-C chemotherapy and
showedacompleteresponse.Bothpatientshadrecurrencein
the bilateral inguinal lymph nodes after 12 and 24 months,
respectively. These 2 patients were treated by superﬁcial
inguinal lymph node dissection and irradiation of the ingu-
inofemoral region. The last patient developed a local
recurrence of the primary tumor and underwent an abdomi-
nal perineal resection. Both patients died after 23 and
26 months follow-up, respectively.
In the group of patients without a SLNB, 1 of 29 patients
(3%) had an inguinal lymph node recurrence (Fig. 1). This
patienthadacT1N0tumorandwastreatedwithirradiationof
the primary tumor with a CR. This patient died at the end of
study period of distant metastasis. After a median follow-up
of 31 months the tumor-related 5 year survival was 76%.
Alteration of Treatment by SLNB
Theguidelinesfortreatmentofanalcarcinomadeveloped
by the Dutch group for gastrointestinal tumors (www.
oncoline.nl) states that irradiation of the inguinal lymph
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tumors. In our study design, SLNB provided alteration
of treatment in at least 11 of the 21 patients: 6 patients with
large T2 tumors ([3 cm) and 3 patients with T3 tumors
revealed tumor-free inguinal SLN and would have received
unnecessaryirradiationunderthestandardtreatmentregime.
There were 2 patients with small T2 tumors not invading the
analcanalupstagedtolymphnodepositivepatientsbasedon
the SLNB, and they received inguinal radiotherapy.
DISCUSSION
Treatment of patients with anal carcinoma and no clin-
ical evidence of lymph node involvement is controversial.
In a series of 153 patients treated with extended irradiation,
inguinal recurrences were observed in only 4 patients
(3%).
8 Prophylactic radiotherapy to inguinal ﬁelds has led
to a decrease of 15%–25% to approximately 3%–4% in the
risk of development of metachronous inguinal metasta-
ses.
9–12 However, in 2 series with a total of 490 patients
treated with chemoradiation that spared the inguinal lymph
nodes if not macroscopically involved, only 7.6% devel-
oped metachronous inguinal metastases.
1,13
In this study we showed that SLNs could be detected in
all patients with anal carcinoma who were eligible for
SLNB. We used a combined
99mTc-labeled nanocolloid
and Patent Blue technique to improve the yield of the
SLNB technique with the lowest false negative rate.
14,15
Currently, 8 studies with a total of 143 patients have been
published that describe the feasibility of SLNB in patients
with squamous carcinoma of the anal carcinoma.
16–23
These studies showed a high SLN detection rate of 96.5%
(138 of 143). The SLN could not be identiﬁed in all cases if
99mTc-nanocolloid was used as the only tracer for the SLN.
Table 1 summarizes the results these 8 studies.
In our study, 2 patients showed inguinal lymph node
metastases after a tumor negative SLNB. Since the lymph
node metastases both were present within 2 years (12 and
24 months), we could consider these metastases as an initial
false-negative SLN. Because most previous studies lack a
long-term follow-up or alteration of the inguinal irradiation
therapybasedontheSLNB,theincidenceofafalse-negative
SLN is not known. The only study with treatment alteration
basedontheSLNBwastherecentstudybyGretschel etal.
23
In that study, 1 patient with a T1 tumor showed inguinal
lymph node recurrence after a tumor-negative SLNB.
To improve the accuracy of the SLNB procedure, lymph
node staging before the SLNB should be optimal. Ultra-
sound in combination with FNA of the lymph node basins
has been used in melanoma, breast, and penile cancer to
optimize the lymph node staging and reduce the number of
unnecessary SLN procedures by 5%–11%.
24–27 In our
study, 1 of the patients with lymph node recurrence after a
tumor-negative SLNB showed suspected deep inguinal
lymph nodes on the ultrasound but a tumor-negative FNA
cytology. Of the 3 other patients with suspected lymph
nodes on the ultrasound and tumor-negative FNA cytology,
2 had a tumor-positive SLNB. One could therefore argue
that in order to improve the accuracy of the SLNB, sus-
pected lymph node on ultrasonography should be treated as
tumor-positive lymph nodes.
Irradiation of the inguinofemoral region can lead to
serious complications with acute and late toxicity. Acute
morbidity includes epidermolysis with ulceration and
superinfection of the skin, while late toxicity includes
inguinal ﬁbrosis, external genitalia edema, neurogenic
bladder, lower limb lymph edema, osteonecrosis of the
femoral head, artery stenosis, and soft tissue sarcomas.
1,12
In our study, 9 patients with T2 and T3 tumors had an
alteration of therapy bases on a negative SLNB and did not
receive groin irradiation. Of the 32 patients who received
radiotherapy of the inguinofemoral basins, the complica-
tions were mainly moderate to severe epidermolysis of the
skin. Because the median follow-up was 31 months, we
could not determine the exact incidence of late toxicity.
However, of the 9 patients who received inguinal radio-
therapy with a follow-up of 5 years there was no incidence
of late irradiation toxicity.
TABLE 1 Studies of SLNB in squamous cell carcinoma of the anal margin and canal
Author Year of
publication
Number
of patients
Dye vs
isotope
SLN(?)/SLN
identiﬁed
Number of cases of
SLN not identiﬁed
Lymphadenectomy
after SLNB
Mean follow-
up (months)
Nodal metastasis
during follow-up
Peley
16 2002 8 Both 2/8 0/8 No 5–35 0/8
Rabbit
17 2002 4 Both 0/4 0/4 No None
Perera
18 2003 12 Both 2/12 0/12 No None
Ulmer
19 2003 17 Isotope 5/13 4/17 No 10 1/16
Damin
20 2003 14 Both 1/14 0/14 No None
Bobin
21 2003 33 Both 7/33 0/33 No 18 0/18
Mistrangelo
22 2008 35 Isotope 7/34 1/35 No 21 0/34
Gretschel
23 2008 20 Isotope 6/20 0/20 No 27 1/20
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SLNB procedure is not without complications. In our study,
24% of patients with a SLNB had a postoperative compli-
cation to the groin after the SLNB procedure. Since 4 of
these 5 patients had a metastasis in the SLN, radiotherapy of
the groin had to be postponed because of inguinal wound
complication. This is in line with the study of Mistrangelo
et al., which found a postoperative complication rate of 57%
including inguinal lymphorrhea, monolateral lymph edema
of the lower limb, and lymphocele.
22 In a recent review of
SLNB in cutaneous squamous cell carcinoma by Ross and
Schmults, adverse events were reported rarely.
6 However,
since inguinal lymph node metastases of anal carcinoma are
treated with irradiation, surgical complications caused by
SLNB can have a negative effect on the morbidity of
inguinal radiotherapy.
Surgical series have shown that about half the inguinal
lymph node with metastasis are less than 5 mm in size.
3
Because these small lymph nodes are not detectable by
palpation or CT imaging, other noninvasive staging
modalities would be more appropriate in patients with
small tumors who otherwise would not be treated with
groin irradiation. In a recent study by Nguyen et al., 18-
FDG PET showed upstaging and alteration of radiotherapy
planning in 18% of N0 patient with anal cancer.
28
We conclude that SLNB in anal cancer following careful
primary selection based on clinical examination, imaging
techniques, and FNA of suspected nodes is technical fea-
sible with a high detection rate of SLNs. SLNB can be used
to upstage clinical node-negative patients with small
tumors who would otherwise refrain from inguinal radio-
therapy. Besides, SLNB can identify those patients who
would beneﬁt from refrain of inguinal irradiation treatment
and thereby reduce the incidence of unnecessary inguinal
radiotherapy. However, because of the occurrence of
inguinal lymph node metastases after a tumor-negative
SLNB, introduction of this procedure as standard of care in
all patients with anal carcinoma should be done with cau-
tion to avoid undertreatment of patient who otherwise
would beneﬁt from inguinal radiotherapy.
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